Micro Learning: Black Cisgender and Trans Women, HIV Treatment, & PrEP
Resource updated 05/10/2023
Resource updated 05/10/2023
Resource updated 09/19/2023
Resource updated 09/19/2023
By cross matching registries of HIV and other sexually transmitted infections, this study found 27.1% of male syphilis cases were coinfected with HIV and 31.8% of those coinfected were not virally suppressed. This suggests ongoing sexual risk behaviors and the potential for HIV transmission among male syphilis cases.
Resource (Conference Presentation) updated 09/14/2023
This HIV clinic evaluated effectiveness of telemedicine for selected patients during the first year of the COVID-19 pandemic, and found overall viral suppression and retention in care rates were not adversely impacted by switch to telemedicine. They also noted similar rates of telemedicine utilization across demographic criteria.
Resource (Conference Presentation) updated 09/14/2023
Utilization of a peer support specialist to increase routine bacterial sexually transmitted infection screening, testing, and treatment in an urban clinic and related patient care outcomes.
Resource (Conference Presentation) updated 09/14/2023
The rationale, methodology, and implementation of New York State's Checklist for Evaluating HIV Telehealth Care as used by HIV providers to assess the quality of their telehealth services.
Resource (Conference Presentation) updated 09/14/2023
BPHC and HIV service agencies in the Boston EMA quickly adapted during the pandemic by shifting to telehealth, streamlining and enhancing processes, and expanding services to accommodate changing client needs. These changes have led to valuable lessons learned to reduce barriers to care, sustain adaptability and modernize service delivery.
Resource (Conference Presentation) updated 09/14/2023
In collaboration with Tennessee Department of Corrections, we developed and implemented a stepwise HIV telemedicine program to optimize viral suppression in the state prisons during 2010-2018. Clinic attendance increased from 50 percent to 90 percent during full implementation. Viral suppression increased from 30 percent in 2010 to 90 percent in 2018.
Resource (Conference Presentation) updated 09/14/2023
California’s AIDS Drug Assistance Program (ADAP) and Pre-Exposure Prophylaxis Assistance Program (PrEP-AP) provide access to life-saving medications and insurance assistance for eligible California residents living with or at risk of acquiring HIV. This presentation will explore the efficacy of various program policy changes implemented by California during the COVID-19 pandemic.
Resource (Conference Presentation) updated 09/14/2023
Review of a 12-month clinical telePrEP program for rural South Carolina residents, which evaluated the feasibility and acceptability of PrEP delivered through a telehealth model.
Resource (Conference Presentation) updated 09/14/2023
Screening protocols developed to identify more opportunities for testing at multiple sites and in asymptomatic individuals among persons at risk individuals with HIV to prevent and treat STIs.
Resource (Conference Presentation) updated 09/14/2023
A NJ clinic has implemented multi-site STI screening for the clinic population and for higher risk groups. Gains made in implementation through prior quality initiatives were not sustained. The clinic worked collaboratively with a quality coach to identify how and why rectal swabs are overlooked, particularly when indicated.
Resource (Conference Presentation) updated 09/14/2023
Introduction. In Louisiana, the rates of sexually transmitted infections (STI) rank among the top ten. Approach. A sexual activity history was completed utilizing an audio computer-assisted self-interview tool. Results. Over 40% of the recommended STI screenings were extragenital testing. Discussion. A sexual activity history tool provides reliable recommendations for STI testing.
Resource (Conference Presentation) updated 09/14/2023
NASTAD’s National AIDS Drug Assistance Program (ADAP) Formulary Database provides an online, searchable, publicly available resource detailing state-by-state ADAP coverage of medications, including HIV antiretroviral (ARV) treatments, “A1” Opportunistic Infections (A1 OI) medications, treatments for hepatitis B and C, mental health and substance use treatment medications, and various vaccines and laboratory tests.
Resource updated 03/07/2024
Resource updated 03/13/2024
Guide to help ADAPs prepare for and manage emergencies in order to ensure continued access to HIV medications.
Resource updated 09/19/2023
Information on HRSA's Office of Pharmacy Affairs, which administers the 340b program, which provides drug discounts to certain federal grantees,
Resource updated 09/20/2023
Healthcare providers can receive no-cost expert clinical consultation in HIV prevention & care, HCV treatment, and substance use management.
Resource updated 09/20/2023
Tools developed by a Part A program to monitor programs and services.
Resource updated 09/19/2023